Program
dotmp SM-153
Also written as “153-Sm-DOTMP (Samarium-153-DOTMP)” and “153Sm-DOTMP”.
Its studies are mostly in Bone Neoplasms, led by 2 companies.
Drug pageDotmp SM-153: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| QSAM Therapeuticsits history only | 10 open or running | phase 1since Aug 4, 2023 | Aug 4, 2023 | none ahead |
| Telix Pharmaceuticals | 11 open or running | phase 1since Jul 30, 2025 | Jul 30, 2025 | Apr 26, 2027phase 1 · NCT07197645 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Telix Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 30, 2025First study: phase 1 study in Bone NeoplasmsFirst studyNCT07197645 · 33 planned · United States
Ahead
- Apr 26, 2027Primary completion: phase 1 study in Bone NeoplasmsNCT07197645
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Telix Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07197645Bone Neoplasms · United States | 1 | Recruiting | Apr 26, 2027 | 33 |
How it is read
Names in the registry
- “153-Sm-DOTMP (Samarium-153-DOTMP)”, 1 entry
- “153Sm-DOTMP”, 1 entry
Conditions, from the studies’ own filings
- Bone Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.